Preparations for Dry Eye and Ocular Surface Disease

Clinical Ocular Pharmacology

Volumn , Issue , 2008, Pages 263-278

  Pensyl, C Denise ^a  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053182252     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7506-7576-5.50019-7     Document Type: Chapter

References (81)

1. Absolon MJ, Brown CA Acetylcysteine in keratoconjunctivitis sicca. Br J Ophthalmol 1968, 52:310-316.
2. Ang RT, Dartt DA, Tsubota K Dry eye after refractive surgery. Curr Opin in Ophthalmol 2001, 12:318-322.
3. Aragona P, Di Stefano G, Ferreri F, et al. Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjögren's syndrome patients. Br J Ophthalmol 2002, 86:879-884.
4. Aragona P, Papa V, Micali A, et al. Long term treatment with sodium-hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol 2002, 86:181-184.
5. Balaram M, Schaumberg DA, Dana MR Efficacy and tolerability outcomes after punctual occlusion with silicone plugs in dry eye syndrome. Am J Ophthalmol 2001, 131:30-36.
6. Beetham WP Filamentary keratitis. Trans Am Ophthalmol Soc 1936, 33:413-435.
7. Bernal DL, Ubels JL Artificial tear composition and promotion of recovery of the damaged corneal epithelium. Cornea 1993, 12:115-120.
8. Blaug SM, Canada AT Relationship of viscosity, contact time, and prolongation of action of methyl-cellulose-containing ophthalmic solutions. Am J Hosp Pharm 1965, 22:662-666.
9. Brown NAP, Bron AJ, Harding JJ, Dewar HM Nutritional supplements and the eye. Eye 1998, 12:127-133.
10. Caffery BE, Richter D, Simpson T, et al. The Canadian dry eye epidemiology study. Adv Exp Med Biol. 1998, 438:805.
11. Calonge M The treatment of dry eye. Surv Ophthalmol 2001, 45(suppl 2):S227-S239.
12. Cermak JM, Krenzer KL, Sullivan RM, et al. Is complete androgen insensitivity syndrome associated with alterations in the meibomian gland and ocular surface?. Cornea 2003, 22:516-521.
13. Condon PI, McEwen CG, Wright M, et al. Double blind, randomized, placebo controlled, crossover, multicentre study to determine the efficacy of 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome. Br J Ophthalmol 1999, 83:1121-1124.
14. Dana MR, Hamrah P Role of immunity and inflammation in corneal and ocular surface disease associated with dry eye. Adv Exp Med Biol 2002, 506:729-738.
15. Dilly PN Structure and function of the tear film. Lacrimal gland, tear film and dry eye syndrome 1994, 239-247. Plenum Press, New York. D.A. Sullivan (Ed.).
16. Doughty MJ, Fonn D, Richter D, et al. A patient questionnaire approach to estimating the prevalence of dry eye symptoms in patients presenting to optometric practices across Canada. Optom Vis Sci 1997, 74:624-631.
17. Fischbarg J Diquafosol tetrasodium Inspire/Allergan/Santen. Curr Opin Invest Drugs 2003, 4:1377-1383.
18. Fox RI, Chan R, Michelson JB, et al. Beneficial effect of artificial tears made with autologous serum in patients with kerato-conjunctivitis sicca. Arthritis Rheum 1984, 27:459-461.
19. Freeman JM Punctal plug: evaluation of a new treatment for dry eyes. Trans Am Acad Ophthalmol Otolaryngol 1975, 79:874-879.
20. Friedlaender MH, Fox RI Punctal occlusion for the treatment of dry eye. Lacrimal gland, tear film and dry eye syndromes 2: basic science and clinical relevance 1998, 1017-1020. Plenum Press, New York. D.A. Sullivan, D.A. Dartt, M.A. Meneray (Eds.).
21. Gilbard J Tear film osmolarity in keratoconjunctivitis sicca. CLAO J 1985, 11:243-250.
22. Gilbard JP, Kenyon KR Tear diluents in the treatment of kerato-conjunctivitis sicca. Ophthalmology 1985, 92:646-650.
23. Gilbard JP, Rossi SR An electrolyte-based solution that increases corneal glycogen and conjunctival goblet-cell density in a rabbit model for keratoconjunctivitis sicca. Ophthalmology 1992, 99:600-604.
24. Gilbard JP, Rossi SR, Heyda KG Ophthalmic solutions, the ocular surface, and a unique therapeutic artificial tear formulation. Am J Ophthalmol 1989, 107:348-355.
25. Gobbels M, Spitznas M Corneal epithelial permeability of dry eyes before and after treatment with artificial tears. Ophthalmology 1992, 99:873-878.
26. Hardberger R, Hanna C, Boyd CM Effect of drug vehicles on ocular contact time. Arch Ophthalmol 1975, 93:42-45.
27. Harris MG, Gee A, Kusumoto R, Lee H Survival of contaminating bacteria in over-the-counter artificial tears. J Am Optom Assoc 1996, 67:676-680.
28. Hartstein I, Khwarg S, Przydryga J An open-label evaluation of HP-guar gellable lubricant eye drops for the improvement of dry eye signs and symptoms in a moderate dry eye adult population. Curr Med Res Opin 2005, 21:255-260.
29. Holly FJ, Lamberts DW Effect of nonisotonic solutions on tear film osmolality. Invest Ophthalmol Vis Sci 1981, 20:236-245.
30. Kobayashi TK, Tsubota K, Takamura E, et al. Effect of retinol palmitate as a treatment for dry eye: a cytological evaluation. Ophthalmologica 1997, 211:358-361.
31. Krishna N, Brow F Polyvinyl alcohol as an ophthalmic vehicle: effect on regeneration of corneal epithelium. Am J Ophthalmol 1964, 57:99-106.
32. Krishna N, Mitchell B Polyvinyl alcohol as an ophthalmic vehicle: effect on ocular structures. Am J Ophthalmol 1965, 59:860-864.
33. Kunert KS, Tisdale AS, Stern ME Effect of cyclosporine ophthalmic emulsion on the number of inflammatory cells and goblet cells in conjunctival biopsies with dry eye. Invest Ophthalmol Vis Sci 1999, 44(suppl):S771.
34. Kunert KS, Tisdale AS, Stern ME, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol 2000, 118:1489-1496.
35. Laibovitz RA, Solch S, Andriano K, et al. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea 1993, 12:315-323.
36. Lee JB, Ryu CH, Kim JH, et al. Comparison of tear secretion and tear film instability after photorefractive keratectomy and laser in situ keratomileusis. J Cataract Refract Surg 2000, 26:1326-1331.
37. Lemp MA Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J 1995, 21:221-232.
38. Lemp MA, Goldberg M, Roddy MR Effect of tear substitutes on tear film breakup time. Invest Ophthalmol 1975, 14:225-258.
39. Lemp MA, Holly FJ Ophthalmic polymers as ocular wetting agents. Ann Ophthalmol 1972, 4:15-20.
40. Limberg MB, McCaa C, Kissling GE, Kaufman HE Topical application of hyaluronic acid and chondroitin sulfate in treatment of dry eyes. Am J Ophthalmol 1987, 103:194-197.
41. Miljanovic B, Trivedi KA, Dana MR, et al. Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. Am J Clin Nutr 2005, 82:887-893.
42. Mishima S, Gasset A, Klyce SD, Baum JL Determination of tear volume and tear flow. Invest Ophthalmol 1966, 5:264-276.
43. Murube J, Murube A, Zhuo C Classification of artificial tears. II. Additive and commercial formulas. Lacrimal gland, tear film, and dry eye syndromes 2: basic science and clinical relevance 1998, 705-715. Plenum Press, New York. D.A. Sullivan, D.A. Dartt, M.A. Meneray (Eds.).
44. Murube J, Paterson A, Murube E Classification of artificial tears. I. Composition and properties. Lacrimal gland, tear film, and dry eye syndromes 2: basic science and clinical relevance 1998, 693-704. Plenum Press, New York. D.A. Sullivan, D.A. Dartt, M.A. Meneray (Eds.).
45. Nelson JD, Farris RL Sodium hyaluronate and polyvinyl alcohol artificial tear preparations. Arch Ophthalmol 1988, 106:484-487.
46. Nelson JD, Friedlainder M, Yeatts RP, et al. Oral pilocarpine for symptomatic relief of keratoconjunctivitis sicca in patients with Sjögren's syndrome. Lacrimal gland, tear film, and dry eye syndromes 2: basic science and clinical relevance 1998, 979-983. Plenum Press, New York. D.A. Sullivan, D.A. Dartt, M.A. Meneray (Eds.).
47. Nepp J, Schauersberger J, Schild G, et al. The clinical use of viscoelastic artificial tears and sodium chloride in dry-eye syndrome. Biomaterials 2001, 22:3305-3310.
48. Norn MS, Opauszki A Effects of ophthalmic vehicles on the stability of the precorneal film. Acta Ophthalmol 1977, 55:23-34.
49. O'Brien PD, Collum LM Dry eye: diagnosis and current treatment strategies. Curr Allergy Asthma Rep 2004, 4:314-319.
50. Oldham GB, Andrews V Control of microbial contamination in unpreserved eyedrops. Br J Ophthalmol 1996, 80:588-591.
51. Papas AS, Fernandez MM, Castano RA, et al. Oral pilocarpine for symptomatic relief of dry mouth and dry eyes in patients with Sjögren's syndrome. Lacrimal gland, tear film, and dry eye syndromes 2: basic science and clinical relevance 1998, 973-978. Plenum Press, New York. D.A. Sullivan, D.A. Dartt, M.A. Meneray (Eds.).
52. Perry H, Donnenfeld E Medications for dry eye syndrome: a drug-therapy. Manag Care 2003, 12(12 suppl):S26-S32.
53. Perry HD, Donnenfeld Dry eye diagnosis and management in 2004. Curr Opin Ophthalmol 2004, 15:299-304.
54. Perry HD, Donnenfeld Topical 0.05% cyclosporin in the treatment of dry eye. Expert Opin Pharmacother 2004, 5:2099-2107.
55. Pflugfelder SC Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004, 137:337-342.
56. Power WJ, Mullaney P, Farrell M, Collum LM Effect of topical cyclosporine A on conjunctival T-cells in patients with secondary Sjögren's syndrome. Cornea 1993, 12:507-511.
57. Prause JU Treatment of keratoconjunctivitis sicca with Lacrisert. Scand J Rheum 1986, 61(suppl):S261-S263.
58. Prydal JI, Artal P, Woon H, Campbell FW Study of human precorneal tear film thickness and structure using laser inter-ferometry. Invest Ophthalmol Vis Sci 1992, 33:2006-2011.
59. Sall K, Stevenson OD, Mundorf TK, Reis BL Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000, 107:631-639.
60. Selek H, Unlu N, Orhan M, Irkec M Evaluation of retinoic acid ophthalmic emulsion in dry eye. Eur J Ophthalmol 2000, 10:121-127.
61. Shimmura S, Masafumi O, Shinozaki K, et al. Sodium hyaluronate eyedrops in the treatment of dry eyes. Br J Ophthalmol 1995, 79:1007-1011.
62. Small DS, Acheampong A, Reis B, et al. Blood concentrations of cyclosporin A during long-term treatment with cyclosporin A ophthalmic emulsions in patients with moderate to severe dry eye disease. J Ocul Pharmacol Ther 2002, 18:411-418.
63. Smith RE The tear film complex. Pathogenesis and emerging therapies for dry eyes. Cornea 2005, 24:1-7.
64. Snibson A, Greaves JL, Soper NDW, et al. Ocular surface residence times of artificial tear solutions. Cornea 1992, 11:288-293.
65. Soong HK, Martin NF, Wagoner MD, et al. Topical retinoid therapy for squamous metaplasia of various ocular surface disorders. A multicenter, placebo-controlled double-masked study. Ophthalmology 1988, 95:1442-1446.
66. Stenbeck A, Ostholm I Ointments for ophthalmic use. Acta Ophthalmol 1954, 43:405-423.
67. Stevenson D, Tauber J, Reis B Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease. Ophthalmology 2000, 107:967-974.
68. Swan KC Use of methylcellulose in ophthalmology. Arch Ophthalmol 1945, 33:378-380.
69. Tauber J, Davitt WF, Bokosky JE, et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea 2004, 23:784-792.
70. Tauber JT A dose-ranging clinical trial to assess the safety and efficacy of cyclosporine ophthalmic emulsion in patients with keratoconjunctivitis sicca. Lacrimal gland, tear film, and dry eye syndromes 2: basic science and clinical relevance 1998, 693-704. Plenum Press, New York. D.A. Sullivan, D.A. Dartt, M.A. Meneray (Eds.).
71. Tsubota K New approaches to dry-eye therapy. Int Ophthalmol Clin 1994, 34:115-128.
72. Turner K, Pflugfelder SC, Ji Z, et al. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporin ophthalmic emulsion. Cornea 2000, 19:492-496.
73. Ubels J, Clousing D, Van Haitsman T, et al. Pre-clinical investigation of the efficacy of an artificial tear solution containing hydroxypropyl-guar gelling agent. Curr Eye Res 2004, 28:437-444.
74. Ubels JL, Dennis MH, Mitchell JH, et al. Biological activity of N-(4-hydroxyphenyl) retinamide-O-glucuronide in corneal and conjunctival cells of rabbits and humans. Curr Eye Res 1995, 14:1115-1124.
75. Wen Q, Kuang K, Yerxa B, et al. Effects of P2Y2 agonists on lipid secretion by cultured rabbit meibocytes. Invest Ophthalmol Vis Sci 2002, 43(suppl). Abstr 3146.
76. Werblin TP, Rheinstrom SD, Kaufman HE The use of slow-release artificial tears in the long-term management of keratitis sicca. Ophthalmology 1981, 88:78-81.
77. Westerhout DI Treatment of dry eyes with aqueous antioxidant eye drops. CLAO J 1991, 19:165-173.
78. Wolback S, Howe P Tissue changes following deprivation of fat-soluble A vitamin. J Exp Med 1925, 42:753-777.
79. WolffE The muco-cutaneous junction of the lid-margin and the distribution of the tear fluid. Trans Ophthalmol Soc UK 1946, 66:291-308.
80. Yen MT, Pflugfelder SC, Feuer WJ The effect of punctual occlusion of tear production, tear clearance, and ocular surface sensation in normal subjects. Am J Ophthalmol 2001, 131:314-323.
81. Yokoi N, Komuro A, Nishida K, Kinoshita S Effectiveness of hyaluronan on corneal epithelial barrier function in dry eye. Br J Ophthalmol 1997, 81:533-536.